Journal
DIABETES OBESITY & METABOLISM
Volume 23, Issue 12, Pages 2785-2794Publisher
WILEY
DOI: 10.1111/dom.14536
Keywords
Glucagon-like peptide-1 receptor agonist; Japanese; oral semaglutide; PIONEER; post hoc; subgroup analyses
Categories
Funding
- Novo Nordisk A/S, Denmark
Ask authors/readers for more resources
The study aimed to evaluate the efficacy and safety of oral semaglutide compared to other drugs in Japanese patients with type 2 diabetes. The results showed that oral semaglutide effectively lowered HbA1c levels and body weight in Japanese patients, with gastrointestinal adverse events being the most common. Overall, oral semaglutide was well tolerated and showed promising results in Japanese patients.
Aims To evaluate, through exploratory post hoc subgroup analyses, the efficacy and safety of oral semaglutide versus comparators in Japanese patients enrolled in the global PIONEER 1, 3, 4 and 8 clinical trials. Materials and Methods Patients were randomized to once-daily oral semaglutide 3, 7 or 14 mg or comparator (placebo, sitagliptin 100 mg or liraglutide 1.8 mg). Change from baseline in glycated haemoglobin (HbA1c) and body weight, and proportions of patients attaining HbA1c <7.0% (53 mmol/mol) and body weight loss >= 5%, were analysed at week 26 for all Japanese patients in each trial separately using the treatment policy estimand (regardless of treatment discontinuation or rescue medication use). Adverse events (AEs) were analysed descriptively. Results Reductions in HbA1c from baseline in Japanese patients were 1.0% to 1.2% (11.3 mmol/mol to 13.3 mmol/mol) and 1.4% to 1.7% (15.7 mmol/mol to 18.3 mmol/mol) for oral semaglutide 7 mg and 14 mg, respectively. HbA1c reductions were similar or greater than with comparators. Body weight reductions were 1.0% to 2.7% and 3.7% to 4.7% for oral semaglutide 7 mg and 14 mg, respectively, and were generally greater with oral semaglutide than comparators. As expected, the main class of AEs was gastrointestinal, and these AEs comprised most commonly mild-to-moderate constipation, nausea and diarrhoea. Conclusions Oral semaglutide appears efficacious and well tolerated in Japanese patients across the type 2 diabetes spectrum.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available